Midas Pharma GmbH
Midas Pharma GmbH, a prominent player in the pharmaceutical industry, is headquartered in Germany and operates extensively across Europe and beyond. Founded in 1994, the company has established itself as a trusted partner in the development and distribution of innovative healthcare solutions. Midas Pharma focuses on contract development and manufacturing, offering a diverse range of services that include drug formulation, regulatory support, and supply chain management. Their commitment to quality and customer-centric approach sets them apart in a competitive market. With a strong emphasis on research and development, Midas Pharma has achieved significant milestones, positioning itself as a leader in the pharmaceutical sector. The company’s dedication to excellence is reflected in its robust portfolio of products and services, catering to the evolving needs of the healthcare landscape.
DitchCarbon Score
How does Midas Pharma GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Midas Pharma GmbH's score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Midas Pharma GmbH's reported carbon emissions
In 2024, Midas Pharma GmbH reported carbon emissions of approximately 230,000 kg CO2e from Scope 1 sources in Germany. This marks an increase from 2023, when emissions were about 201,000 kg CO2e. On a global scale, the company’s total emissions for 2024 included 249,000 kg CO2e from Scope 1, 16,000 kg CO2e from Scope 2, and a significant 679,714,000 kg CO2e from Scope 3 emissions, which primarily stemmed from purchased goods and services (approximately 678,587,000 kg CO2e). Despite these figures, Midas Pharma GmbH has not established specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to the Science Based Targets initiative (SBTi). The company’s emissions data is not cascaded from any parent organization, indicating that these figures are independently reported. Overall, while Midas Pharma GmbH has made strides in transparency regarding its emissions, the lack of defined climate commitments suggests an opportunity for further engagement in sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 217,000 | 000,000 |
| Scope 2 | 16,000 | 00,000 |
| Scope 3 | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Midas Pharma GmbH is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
